Related Experiment Videos
The antigen-presenting cell function of Reed-Sternberg cells
J Delabie1, W C Chan, D D Weisenburger
1Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha 68198-3115, USA.
Leukemia & Lymphoma
|June 1, 1995
Summary
Reed-Sternberg cells in Hodgkin's disease act as potent antigen-presenting cells (APCs). Their expression of key molecules suggests a crucial role in disease pathogenesis and potential for immunotherapy.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Reed-Sternberg cells are the characteristic neoplastic cells in Hodgkin's disease.
- Antigen-presenting cells (APCs) are crucial for initiating adaptive immune responses.
- Understanding the function of Reed-Sternberg cells is key to Hodgkin's disease pathogenesis.
Purpose of the Study:
- To investigate the antigen-presenting cell (APC) capabilities of Reed-Sternberg cells.
- To determine the expression of key molecules involved in T cell stimulation by Reed-Sternberg cells.
- To explore the implications of Reed-Sternberg cell APC function in Hodgkin's disease.
Main Methods:
- Analysis of Reed-Sternberg cell expression of major histocompatibility complex (MHC) class II antigens, B7 proteins, ICAM-1, and LFA-3.
- In vitro studies using Hodgkin's disease-derived cell lines in mixed lymphocyte cultures.
- Assessment of the role of expressed molecules in T cell stimulation.
Main Results:
- Reed-Sternberg cells express all necessary molecules (MHC class II, B7 proteins, ICAM-1, LFA-3) to function as APCs.
- These molecules are expressed in nearly all Hodgkin's disease subtypes.
- Hodgkin's disease cell lines effectively stimulate mixed lymphocyte cultures, dependent on expressed molecules.
Conclusions:
- Reed-Sternberg cells function as APCs in vivo, representing a common denominator in Hodgkin's disease.
- This APC function does not support a dendritic cell origin for Reed-Sternberg cells.
- Further analysis of antigens expressed by Reed-Sternberg cells could advance understanding and guide immunotherapy development.